SIETES :: 92850 citas

Resultados de la búsqueda por TROMBOCITOPENIA REFINAR BÚSQUEDA

1.

Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]

2.

Anónimo. Fostamatinib fails to show statistically significant results among patients with chronic immune thrombocytopenia. DIA Daily 2016:5. [Ref.ID 100840]

3.

Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388:45-54. [Ref.ID 100482]

4.

Chaturvedi S, McCrae KR. Treatment of chronic immune thrombocytopenia in children with romiplostim. Lancet 2016;388:4-6. [Ref.ID 100480]

5.

Catalá-López F, Corrales I, de la Fuente-Honrubia C, González-Bermejo D, Martín-Serrano G, Montero D, Saint-Gerons DM. Riesgo de tromboembolismo con agonistas del receptor de la trombopoyetina en pacientes adultos con trombocitopenia: revisión sistemática y metaanálisis de ensayos clínicos aleatorizados y controlados. Med Clin (Barc) 2015;145:511-9. [Ref.ID 99778]

6.

Anónimo. Allopurinol + azathioprine: aplasies médullaires. Prescrire 2015;35:672. [Ref.ID 99720]

7.

Anónimo. Eltrombopag et thrombopénie chez les patients atteints d'hépatite C. Prescrire 2015;35:250-1. [Ref.ID 99123]

8.

Ghanima W, Khelif A, Waage A, Michel M, Tjonnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA, on behalf of the RITP study group. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015;385:1653-61. [Ref.ID 99071]

9.

Anónimo. Régorafénib: hypersensibilités multiorganiques. Prescrire 2014;34:749. [Ref.ID 98265]

10.

Anónimo. Interferon beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome. Drug Safety Update 2014;8:A1. [Ref.ID 98101]

11.

Anónimo. Abiratérone: thrombopénies. Prescrire 2014;34:353. [Ref.ID 97562]

12.

Cossu AP, Musu M, Mura P. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. Eur J Clin Pharmacol 2014;70:23-8. [Ref.ID 97004]

13.

Green D. Ibrutinib for mantle-cell lymphoma. Journal Watch 2013:23 de julio. [Ref.ID 96312]

14.

Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Kearman M, Musselman D, Agarwal S, Green J, Kavanaugh A, on behalf of the ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50. [Ref.ID 95382]

15.

De Vita S. Tocilizumab versus adalimumab for rheumatoid arthritis. Lancet 2013;381:1515-7. [Ref.ID 95376]

16.

Gudbrandottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, Klausen TW, Larsen H, Mourits-Andersen HT, Nielsen CH, Nielsen OJ, Plesner T, Pulczynski S, Rasmussen IH, Ronnov-Jessen D, Hasselbalch HC. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013;121:1976-81. [Ref.ID 95137]

17.

Hampton T. Safer cancer drug. JAMA 2013;309:431. [Ref.ID 94913]

18.

Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]

19.

Anónimo. FDA approves Pomalyst for advanced multiple myeloma. U.S. Food and Drug Administration 2013:8 de febrero. [Ref.ID 94691]

20.

Anónimo. Etifoxine: trop d'effets indésirables graves. Prescrire 2013;33:25. [Ref.ID 94676]